Curanex Pharmaceuticals (CURX) Free Cash Flow (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Free Cash Flow came in at -$857404.0 in Q4 2025, down 798.49% YoY from $122750.7 in Q4 2024, and up 90.67% on a QoQ basis from -$9.2 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Free Cash Flow (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Free Cash Flow data on file, last reported at -$857404.0 in Q4 2025.
- Quarterly Free Cash Flow fell 798.49% year-over-year to -$857404.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.1 million (changed N/A YoY) and the FY2025 annual result came in at -$10.5 million, down 1787.14% from the prior year.
- Free Cash Flow climbed to -$857404.0 in Q4 2025, from -$9.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$95427.0 in Q4 2024 to a low of -$9.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | -857,404.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -857,404.00 |
| Dec 31, 2025 | -857,404.00 |
| Sep 30, 2025 | -9.19 Mn |
| Sep 30, 2025 | -9.19 Mn |
| Dec 31, 2024 | -95,427.00 |
| Dec 31, 2024 | -95,427.00 |
| Sep 30, 2024 | -129,943.00 |
| Sep 30, 2024 | -129,943.00 |